Smoking cessation

Germany Set to Enhance Health and Productivity through Expanding Corporate Wellness Market - ResearchAndMarkets.com

Retrieved on: 
Lunedì, Maggio 6, 2024
Fitness & Nutrition, Health, Workforce, Environment, Culture, Smoking cessation, B2B, Ecosystem, Quality of life, Growth, Management

The "Germany Corporate Wellness Market - Forecasts from 2024 to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Germany Corporate Wellness Market - Forecasts from 2024 to 2029" report has been added to ResearchAndMarkets.com's offering.
  • Germany's corporate landscape demonstrates a keen focus on customizing wellness programs tailored to address the specific needs of the workforce.
  • Services such as stress management, dietary consultations, mental health support, and fitness are diversifying to meet the dynamic prerequisites of corporate wellness.
  • In attempting to alleviate the soaring costs induced by chronic health conditions, corporate wellness programs are perceived as strategic investments.

2024 World Brain Day Dedicated to Brain Health and Prevention

Retrieved on: 
Martedì, Maggio 7, 2024
Public, World government, Myenteric plexus, Mayo Clinic, Stroke, Parkinson's disease, WHO, Social media, Neurological disorder, World Health Organization, Policy, Risk, WBD, Guest, Health care, MD, Life, Alzheimer's disease, Culture, Exercise, Smoking cessation, Encephalitis, Society, Diet, Meningitis, DSM-IV codes, Movement, Epilepsy, Multiple sclerosis, Dementia, Sleep, WFN

LONDON, May 7, 2024 /PRNewswire/ -- The World Federation of Neurology (WFN) is pleased to announce Brain Health and Prevention as the theme for the 2024 World Brain Day (WBD 2024), taking place on Monday, July 22.

Key Points: 
  • LONDON, May 7, 2024 /PRNewswire/ -- The World Federation of Neurology (WFN) is pleased to announce Brain Health and Prevention as the theme for the 2024 World Brain Day (WBD 2024), taking place on Monday, July 22.
  • "This World Brain Day is a chance for us to unite and advocate for our present and future," says Prof. Tissa Wijeratne, World Brain Day Co-Chair.
  • "As we approach World Brain Day 2024, let's come together to support brain health and prevention.
  • Mark your calendars for July 22—a day dedicated to celebrating brain health and promoting prevention.

2024 World Brain Day Dedicated to Brain Health and Prevention

Retrieved on: 
Martedì, Maggio 7, 2024
Public, World government, Myenteric plexus, Mayo Clinic, Stroke, Parkinson's disease, WHO, Social media, Neurological disorder, World Health Organization, Policy, Risk, WBD, Guest, Health care, MD, Life, Alzheimer's disease, Culture, Exercise, Smoking cessation, Encephalitis, Society, Diet, Meningitis, DSM-IV codes, Movement, Epilepsy, Multiple sclerosis, Dementia, Sleep, WFN

LONDON, May 7, 2024 /PRNewswire/ -- The World Federation of Neurology (WFN) is pleased to announce Brain Health and Prevention as the theme for the 2024 World Brain Day (WBD 2024), taking place on Monday, July 22.

Key Points: 
  • LONDON, May 7, 2024 /PRNewswire/ -- The World Federation of Neurology (WFN) is pleased to announce Brain Health and Prevention as the theme for the 2024 World Brain Day (WBD 2024), taking place on Monday, July 22.
  • "This World Brain Day is a chance for us to unite and advocate for our present and future," says Prof. Tissa Wijeratne, World Brain Day Co-Chair.
  • "As we approach World Brain Day 2024, let's come together to support brain health and prevention.
  • Mark your calendars for July 22—a day dedicated to celebrating brain health and promoting prevention.

Philadelphia Direct Primary Care Provider Dr. Lily Girson Announces the Grand Opening of Mindful Medicine and Wellness MD

Retrieved on: 
Giovedì, Maggio 2, 2024
Telehealth, Sport, Suite, Heart, Wellness, Insurance, Conestoga Road, Medicine, Smoking cessation, Direct, Patient, DPC, Nursing

NARBERTH, Pa., May 2, 2024 /PRNewswire-PRWeb/ -- Mindful Medicine and Wellness MD is excited to announce the grand opening of its new Direct Primary Care practice, offering patients unprecedented access, personalized attention, and comprehensive healthcare services. Led by board-certified primary care physician Dr. Lily Girson, the practice aims to revolutionize the doctor-patient relationship by prioritizing compassion, prevention, and holistic wellness.

Key Points: 
  • Mindful Medicine and Wellness MD, led by board-certified primary care physician Dr. Lily Girson, announces the grand opening of its new Direct Primary Care practice.
  • NARBERTH, Pa., May 2, 2024 /PRNewswire-PRWeb/ -- Mindful Medicine and Wellness MD is excited to announce the grand opening of its new Direct Primary Care practice , offering patients unprecedented access, personalized attention, and comprehensive healthcare services.
  • Led by board-certified primary care physician Dr. Lily Girson , the practice aims to revolutionize the doctor-patient relationship by prioritizing compassion, prevention, and holistic wellness.
  • "At Mindful Medicine and Wellness MD, we believe in practicing medicine the way it should be – with more time, more access, and more care," said Dr. Lily Girson.

Plume Clinic Announces Contracts with Payers, Lab Partners to Broaden Access to Gender Affirming Care for Trans Community in Illinois

Retrieved on: 
Mercoledì, Aprile 17, 2024
Blue Shield, Acne, Cigna, Trans, Insurance, Depression, Birth, Environment, Plume, Smoking cessation, Patient, Blue Cross, Labcorp, Allergy, UnitedHealth Group, Anxiety, Nursing

"Plume is unique in that it is exclusively focused on serving the needs of the trans community.

Key Points: 
  • "Plume is unique in that it is exclusively focused on serving the needs of the trans community.
  • According to the Williams Institute1, an estimated 43,400 trans adults (18+) live in Illinois.
  • Approximately 87 percent of trans individuals are covered under a health benefit plan, according to the 2022 U.S. Trans Survey2.
  • Services offered through Plume includes access to gender affirming care, as well as treatment for common health issues such as anxiety, depression, allergies, contraception, acne, smoking cessation and more.

The Truth About ZONNIC: New Educational Campaign Tackles Misinformation About Nicotine Pouches

Retrieved on: 
Giovedì, Aprile 11, 2024
Sale, Imperial Tobacco Canada, Health Canada, Minor, Smoker, Smoking cessation, Smoking, Incidence, Marketing, NRT, Tobacco

Frank Silva, President and CEO of ITCAN, stated, "Our new ZONNIC campaign fact checks what's being said about ZONNIC nicotine pouches and reflects our dedication to harm reduction and our commitment to help reduce smoking rates in Canada."

Key Points: 
  • Frank Silva, President and CEO of ITCAN, stated, "Our new ZONNIC campaign fact checks what's being said about ZONNIC nicotine pouches and reflects our dedication to harm reduction and our commitment to help reduce smoking rates in Canada."
  • Since launch in October, ZONNIC nicotine pouches and ITCAN have been targeted by anti-tobacco lobby groups and by the Federal Minister of Health with accusations and inaccuracies.
  • The company is now setting the record straight by shedding light on the truth about ZONNIC.
  • The launch of The Truth About ZONNIC campaign will allow ITCAN to dispel myths about ZONNIC nicotine pouches and to demonstrate how ITCAN has gone above and beyond to ensure ZONNIC is not accessible to youth.

Conversio Health Delivers Improved Patient Outcomes and Reduced Costs with Groundbreaking COPD and Asthma Disease Management Program

Retrieved on: 
Giovedì, Febbraio 8, 2024
Communication, COPD, Education, SAN, Pharmacy, Health, Smoking cessation, Health education, Smart device, Patient, Hospital, Nursing

SAN LUIS OBISPO, Calif., Feb. 8, 2024 /PRNewswire-PRWeb/ -- Conversio Health, the leading innovator in respiratory disease care, today announced the success of its pioneering COPD and Asthma disease management program—significantly improving patient outcomes and reducing costs for patients and healthcare stakeholders. Their program has grown rapidly over the past 18 months, consistently partnering with new provider groups and health plans. The Conversio Health chronic respiratory management program delivers the most comprehensive patient care solution:

Key Points: 
  • New website for Conversio's disease management program highlights significant improvements in patient care and cost associated with chronic respiratory conditions.
  • SAN LUIS OBISPO, Calif., Feb. 8, 2024 /PRNewswire-PRWeb/ -- Conversio Health, the leading innovator in respiratory disease care, today announced the success of its pioneering COPD and Asthma disease management program—significantly improving patient outcomes and reducing costs for patients and healthcare stakeholders.
  • Their program has grown rapidly over the past 18 months, consistently partnering with new provider groups and health plans.
  • The Conversio Health chronic respiratory management program delivers the most comprehensive patient care solution:
    Custom Nebulizer Medications: Improve drug delivery & lung penetration and provide cost savings to patients & health plans.

Pusan National University Researchers Decode the Link Between Smoking and Amyotrophic Lateral Sclerosis Risk

Retrieved on: 
Martedì, Gennaio 30, 2024
Woman, Assistant, Patient, Risk, ALS, Meta-analysis, Tobacco Induced Diseases, Smoking, Female, Systematic review, Pusan National University, Public, PICO, Odds ratio, Smoker, Smoking cessation, Informatics, Health informatics, Area studies, Pharmaceutical industry

This treatment gap highlights the need to identify risk factors, particularly modifiable ones, that could potentially prevent the onset of ALS.

Key Points: 
  • This treatment gap highlights the need to identify risk factors, particularly modifiable ones, that could potentially prevent the onset of ALS.
  • While smoking has been considered a significant risk, studies have yielded inconclusive results, failing to pinpoint the exact association.
  • Identifying smoking as a modifiable risk factor highlights the potential for mitigating the risk of developing ALS through smoking cessation.
  • Title of original paper: Association of smoking with amyotrophic lateral sclerosis: A systematic review, and meta-analysis, including dose-response analysis

Partnership-funded initiative has increased access to smoking cessation support for people with cancer

Retrieved on: 
Mercoledì, Gennaio 24, 2024
Family, Smoker, Hospital, Smoking, Health, Bladder cancer, Smoking cessation, Survival, Friends, Partnership, Mental health, First Nations, Lung cancer, Risk, Nicotine, Canadian Cancer Society, Acupuncture, Hypnosis, Smoke

For people with cancer, quitting smoking after a cancer diagnosis can make a big difference.

Key Points: 
  • For people with cancer, quitting smoking after a cancer diagnosis can make a big difference.
  • By quitting smoking, a person's cancer treatment becomes more effective and their chance of survival increases by about 40 per cent – making smoking cessation support a critical component of initial cancer treatment and high-quality cancer care.
  • When the Partnership began leading this pan-Canadian initiative to integrate evidence-based smoking cessation into cancer care across Canada, only two provinces were actively helping people with cancer quit smoking.
  • Impact of a Pan-Canadian Initiative, visit Smoking cessation in cancer care across Canada, 2022-23 – Canadian Partnership Against Cancer .

Qnovia, Inc. announces positive results from first-in-human pharmacokinetic and safety study of lead asset QN-01, a prescription inhaled smoking cessation therapy

Retrieved on: 
Mercoledì, Novembre 29, 2023
Science, Other Science, Pharmaceutical, Health, Tobacco, Health Technology, Clinical Trials, Retail, Smoker, IND, Plasma, MHRA, Patient, Multimedia, Smoke, Nicotine, Tmax, Initial, Pharmacokinetics, CDER, Medication, Therapy, NRT, Cmax, CTA, Smoking cessation, Smoking, Pharmaceutical industry, Research

Qnovia, Inc., a pharma company developing inhaled therapeutics across a variety of indication areas leveraging its proprietary inhaled drug delivery platform, the RespiRxTM, today announced positive results from its first in-human study of QN-01, the company’s lead asset.

Key Points: 
  • Qnovia, Inc., a pharma company developing inhaled therapeutics across a variety of indication areas leveraging its proprietary inhaled drug delivery platform, the RespiRxTM, today announced positive results from its first in-human study of QN-01, the company’s lead asset.
  • QN-01 is an inhaled smoking cessation therapy that is currently being evaluated in the U.S. under FDA’s Center for Drug Evaluation and Research (CDER) and in the U.K. by the Medicines and Healthcare Products Regulatory Agency (MHRA).
  • “We are delighted to share that QN-01 demonstrated a superior pharmacokinetic profile compared to an existing inhaled NRT and was well tolerated.
  • The drug-device combination was well tolerated with no severe adverse events and few minor adverse events typical of inhaled nicotine.